Akero Therapeutics Ownership | Who Owns Akero Therapeutics?

Akero Therapeutics Ownership Summary

Akero Therapeutics is owned by 106.82% institutional investors, 2.54% insiders. Wellington management group llp is the largest institutional shareholder, holding 10.62% of AKRO shares. Vanguard Health Care Inv is the top mutual fund, with 5.77% of its assets in Akero Therapeutics shares.

AKRO Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Akero Therapeutics	106.82%	2.54%	-9.36%
Sector	Healthcare Stocks	57.39%	9.93%	32.68%
Industry	Biotech Stocks	68.48%	9.65%	21.87%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Wellington management group llp	7.38M	10.62%	$205.23M
Rtw investments, lp	6.86M	9.88%	$190.84M
Blackrock	5.59M	9.42%	$131.06M
Janus henderson group	6.03M	8.69%	$167.77M
Blackrock funding, inc. /de	5.92M	8.53%	$164.81M
General atlantic	5.23M	7.54%	$145.61M
Price t rowe associates inc /md/	4.32M	6.22%	$120.24M
Vanguard group	3.70M	5.33%	$103.06M
State street	2.34M	3.36%	$64.99M
Boxer capital	1.68M	2.83%	$39.34M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Propel bio management	343.73K	9.50%	$9.56M
University of wisconsin foundation	410.63K	8.30%	$11.42M
General atlantic	5.23M	5.18%	$145.61M
Foresite capital management vi	365.00K	4.52%	$10.15M
Silverarc capital management	739.56K	4.50%	$20.57M
Rtw investments, lp	6.86M	2.89%	$190.84M
Cutter capital management, lp	230.00K	2.62%	$6.40M
Logos global management lp	800.00K	2.60%	$22.26M
Redmile group	1.24M	2.39%	$34.36M
Boxer capital	1.68M	2.07%	$39.34M

Top Buyers

Holder	Shares	% Assets	Change
Rtw investments, lp	6.86M	2.89%	940.39K
Deep track capital, lp	1.49M	1.55%	800.22K
Blackrock	5.59M	0.00%	694.02K
Balyasny asset management	649.13K	0.03%	649.13K
Pfizer	562.63K	0.60%	562.63K

Top Sellers

Holder	Shares	% Assets	Change
Alkeon capital management	1.76M	0.10%	-1.56M
Braidwell lp	-	-	-1.08M
Janus henderson group	6.03M	0.09%	-1.04M
T. rowe price investment management	670.05K	0.01%	-630.05K
Perceptive advisors	1.19M	0.91%	-529.21K

New Positions

Holder	Shares	% Assets	Change	Value
Balyasny asset management	649.13K	0.03%	649.13K	$18.06M
Pfizer	562.63K	0.60%	562.63K	$15.65M
Foresite capital management vi	365.00K	4.52%	365.00K	$10.15M
Marshall wace, llp	275.07K	0.01%	275.07K	$7.65M
Cutter capital management, lp	230.00K	2.62%	230.00K	$6.40M

Sold Out

Holder	Change
Farther finance advisors	-1.00
Newedge advisors	-7.00
Nelson, van denburg & campbell wealth management group	-12.00
Riggs asset managment	-14.00
Continuum advisory	-18.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Dec 31, 2024	198	10.00%	74,179,472	1.61%	106	0.97%	107	27.38%	50	-12.28%
Sep 30, 2024	180	14.65%	72,997,386	1.71%	105	0.72%	85	8.97%	57	7.55%
Jun 30, 2024	157	-15.14%	71,768,872	-1.77%	121	0.80%	78	-29.09%	53	12.77%
Mar 31, 2024	185	8.82%	73,065,461	23.85%	123	1.10%	110	25.00%	47	-2.08%
Dec 31, 2023	170	-21.30%	58,992,846	3.30%	105	1.00%	88	-29.60%	48	29.73%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Vanguard Health Care Inv	4.40M	5.77%	-
Vanguard Total Stock Mkt Idx Inv	2.29M	3.01%	166.68K
Vanguard US Total Market Shares ETF	1.94M	2.55%	2.50K
iShares Russell 2000 ETF	1.96M	2.46%	-17.00K
T. Rowe Price New Horizons	1.81M	2.38%	-24.48K
US Small-Cap Growth II Equity Comp	1.81M	2.38%	29.50K
Janus Henderson Global Life Sciences	1.64M	2.15%	-378.12K
Janus Henderson Global Life Sciences D	1.56M	2.04%	-68.31K
Janus Global Life Science AUSD	1.30M	1.71%	-193.92K
T. Rowe Price Health Sciences	1.24M	1.63%	-18.77K

Recent Insider Transactions

Date	Name	Role	Activity	Value
Apr 15, 2025	Yale Catriona	Chief Development Officer	Sell	$46.34K
Apr 15, 2025	Yale Catriona	Chief Development Officer	Sell	$297.62K
Apr 10, 2025	Cheng Andrew	President and CEO	Sell	$1.06M
Apr 07, 2025	Rolph Timothy	Chief Scientific Officer	Sell	$77.78K
Apr 07, 2025	Rolph Timothy	Chief Scientific Officer	Sell	$3.69K

Insider Transactions Trends

Date	Buy	Sell
2025 Q2	-	7
2025 Q1	4	39
2024 Q4	-	31
2024 Q3	-	26
2024 Q2	-	10

AKRO Ownership FAQ

Who Owns Akero Therapeutics?

Akero Therapeutics shareholders are primarily institutional investors at 106.82%, followed by 2.54% insiders and -9.36% retail investors. The average institutional ownership in Akero Therapeutics's industry, Biotech Stocks , is 68.48%, which Akero Therapeutics exceeds.

Who owns the most shares of Akero Therapeutics?

Akero Therapeutics’s largest shareholders are Wellington management group llp (7.38M shares, 10.62%), Rtw investments, lp (6.86M shares, 9.88%), and Blackrock (5.59M shares, 9.42%). Together, they hold 29.92% of Akero Therapeutics’s total shares outstanding.

Does Blackrock own Akero Therapeutics?

Yes, BlackRock owns 9.42% of Akero Therapeutics, totaling 5.59M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 131.06M$. In the last quarter, BlackRock increased its holdings by 694.02K shares, a 14.19% change.

Who is Akero Therapeutics’s biggest shareholder by percentage of total assets invested?

Propel bio management is Akero Therapeutics’s biggest shareholder by percentage of total assets invested, with 9.50% of its assets in 343.73K Akero Therapeutics shares, valued at 9.56M$.

Who is the top mutual fund holder of Akero Therapeutics shares?

Vanguard Health Care Inv is the top mutual fund holder of Akero Therapeutics shares, with 5.77% of its total shares outstanding invested in 4.4M Akero Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools